NeuroBo To Present Latest Pre-Clinical Data On Cardiometabolic Assets, DA-1241 And DA-1726, Targeting MASH And Obesity, At Scientific Conferences In June
Portfolio Pulse from Benzinga Newsdesk
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced its cardiometabolic assets, DA-1241 and DA-1726, will be presented at the EASL Congress 2024 and the ADA 84th Scientific Sessions in June. DA-1241 has completed enrollment for Part 1 of its Phase 2a clinical trial for MASH treatment, and DA-1726 has begun its Phase 1 trial for obesity treatment. Top-line data for DA-1726 is expected in Q3 2024 and Q1 2025. The presentations highlight the pre-clinical data's recognition and the progress of both programs.
April 30, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroBo Pharmaceuticals, Inc. (NRBO) is set to present its cardiometabolic assets, DA-1241 and DA-1726, at prestigious scientific conferences, indicating significant progress in their development for treating MASH and obesity.
The acceptance of NeuroBo's DA-1241 and DA-1726 for presentation at key scientific conferences underscores the scientific community's interest in these assets and their potential market impact. The completion of enrollment for DA-1241's Phase 2a trial and the initiation of DA-1726's Phase 1 trial, along with the expected release of top-line data, are positive indicators of progress in their development. This news is likely to be viewed positively by investors, potentially leading to a short-term uptick in NRBO's stock price as it reflects both the advancement of NeuroBo's pipeline and the potential for future revenue generation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100